Brookline Capital (NASDAQ:BCAC) announced in an 8-K this morning that its shareholders approved its combination with Apexigen at a special meeting July 27.
The filing did not include redemption figures, but the transaction also did not have a minimum cash condition beyond listing requirements. Brookline brought a $15 million PIPE alongside its trust in the deal and Lincoln Park also agreed to purchase up to $50 million of the combined entity’s stock in the two years following the transaction’s close.
Brookline traded below its estimated pro rata trust value of $10.22 throughout its July 25 redemption deadline, but has since soared to a close Wednesday at $10.75. Following the deal’s close, Apexigen is expected to trade on the Nasdaq under the symbol “APGN”.
The parties initially announced the $278 million combination on March 18. San Carlos, California-based Apexigen is developing a range of immunological cancer treatments with four currently in Phase II trials.
It announced the results of its Phase II trials to treat pancreatic cancer with its sotigalimab drug candidate in June.
ADVISORS
- Brookline Capital Markets is acting as capital markets advisor to Brookline Capital Acquisition Corp.
- Wedbush PacGrow is acting as exclusive strategic financial advisor to Apexigen.
- DLA Piper LLP (US) is serving as legal advisor to Brookline Capital Acquisition Corp.
- Wilson Sonsini Goodrich & Rosati, P.C. is serving as legal advisor to Apexigen.
At the SPAC of Dawn After what appeared to a pause in activity around the presidential debate, Southport (OTC:PORT) and Future Vision II (NASDAQ:FVNNU) broke the seal yesterday on both new business combinations and IPOs, respectively. Two SPACs are about to come off of the board as well, however, as 99 Acquisition Group (NASDAQ:NNAG) has...
Future Vision II Acquisition Corp. announced the pricing of its $50 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “FVNNU”, Friday, September 12, 2024. The new SPAC intends to focus its search on businesses within the technology, media, and telecommunications sector. Future Vision II’s sponsor team is...
Southport (OTC:PORT) has entered into a definitive agreement to combine with Angel Studios at a pro forma enterprise value of $1.56 billion. Angel Studios produces film and TV content for both streaming and theatrical releases. The combined company is expected to trade on the NYSE or Nasdaq under the symbol “AGSD” once the deal is...
At the SPAC of Dawn Anyone hoping for fireworks at last night’s US presidential debate was unlikely to have been disappointed. But, for many industries and family pets just hoping to be left out of it, it was no dice. On the SPAC side of things, of course no de-SPAC is more tied to this...
At the SPAC of Dawn The market may be in for a rollercoaster 24 hours of macro indicators. Just as the first presidential debate reset market expectations about the political direction of the US, so too did a switch at the top of the ticket by one of the major parties. At 9 pm ET...